{"id":4431,"date":"2026-11-19T09:00:00","date_gmt":"2026-11-19T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4431"},"modified":"2026-11-19T20:46:06","modified_gmt":"2026-11-20T00:46:06","slug":"in-vivo-dual-car-t-design-opens-tumor-vasculature","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4431","title":{"rendered":"In Vivo Dual CAR T Design Opens Tumor Vasculature"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"393\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261119_Li_Dual_CAR_T_Technology_and_Modalities-768x393.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4442\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261119_Li_Dual_CAR_T_Technology_and_Modalities-768x393.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261119_Li_Dual_CAR_T_Technology_and_Modalities-300x154.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261119_Li_Dual_CAR_T_Technology_and_Modalities-1024x524.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261119_Li_Dual_CAR_T_Technology_and_Modalities-1536x786.png 1536w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261119_Li_Dual_CAR_T_Technology_and_Modalities.png 1752w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Academic (China-based group, Nature Communications)<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>Peer-reviewed publication<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>mRNA-LNP in vivo dual CAR T<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>VEGFR2-directed plus tumor-antigen-directed CAR T populations<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>VEGFR2; tumor antigen<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Melanoma and colorectal cancer (mouse models)<\/p>\n<h4>Summary<\/h4>\n<p>A peer-reviewed Nature Communications article published online November 19 reports an mRNA lipid nanoparticle system that programs two complementary CAR T populations in vivo: one targeting VEGFR2-positive tumor vasculature and one targeting a tumor antigen. Mouse models showed improved infiltration and tumor control.<\/p>\n<p>The China-based academic group used an LNP approach to transfect endogenous T cells, with a VEGFR2-directed subset transiently remodeling endothelium before tumor-directed cytotoxicity. Melanoma and colorectal tumor models were preclinical; no human efficacy or clinical manufacturability was reported.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> coordinated vascular opening may address a central barrier to solid-tumor cell therapy and bypass autologous ex-vivo manufacturing.<\/p>\n<p><strong>Interpretation B:<\/strong> vascular disruption can injure healthy tissue, and murine trafficking may not predict human biodistribution or immune activation. A two-product pharmacology inside one host complicates dose control, PK\/PD, receptor expression persistence, cytokine risk and release testing. LNP tropism, repeat-dose immunogenicity, tumor antigen heterogeneity and VEGFR2 expression on normal endothelium remain decisive translational constraints. Patent filing is disclosed, but licensing and freedom to operate are unresolved.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>CAR T cells are engineered immune cells bearing antigen-recognition receptors. VEGFR2 is expressed in vascular endothelium; the proposed first CAR population modifies access while the second attacks malignant cells.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Primary journal article supports preclinical design and data.<\/li>\n<li>Missing: quantitative human-cell biodistribution, repeated dosing, off-tissue vascular effects and scalable GMP manufacture.<\/li>\n<li>Upgrade: humanized systems with tissue safety margins.<\/li>\n<li>Downgrade: normal vascular injury.<\/li>\n<li>Falsifier: no added tumor infiltration at clinically tolerable VEGFR2 exposure.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>This is a credible frontier platform hypothesis, not a treatment-ready solid-tumor CAR T.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 4 of 5. Signal Direction: uncertain. Confidence in Facts: High. Confidence in Interpretation: Low to Moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A peer-reviewed Nature Communications article published online November 19 reports an mRNA lipid nanoparticle system that programs two complementary CAR T populations in vivo: one targeting VEGFR2-positive tumor vasculature and one targeting a tumor&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4442,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[1440,1550,1549],"class_list":["post-4431","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-in-vivo-car-t-2","tag-lipid-nanoparticles","tag-vegfr2"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4431","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4431"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4431\/revisions"}],"predecessor-version":[{"id":4447,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4431\/revisions\/4447"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4442"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4431"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4431"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4431"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}